Navigation Links
OncoGenex Reports First Quarter Financial Results
Date:5/7/2009

ogenex.com" target="_new">www.oncogenex.com.

This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including statements concerning the Company's key objectives for 2009, and other anticipated activities, achievements, occurrences and performance. These statements are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements. All statements other than statements of historical fact are statements that could be deemed forward-looking statements.

The potential risks and uncertainties associated with forward-looking statements include, among others, the timing and costs of clinical trials and regulatory approvals, risks that clinical trials will not be successful or confirm earlier or interim clinical trial results, the Company's need for additional financing, the uncertainty associated with any potential partnering discussions, risks relating to the development, safety and efficacy of therapeutic drugs and potential applications for these products and the risk factors set forth in the Company's filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for fiscal year 2008 and its Quarterly Report for the first quarter of 2009 on Form 10-Q. No assurances can be given that any of the events anticipated by the forward-looking statements will transpire or occur, or that if any of them do transpire or occur, what impact they would have on the results of operations or financial condition of the Company. The Company undertakes no obligation to update the forward-looking statements contained herein or to reflect events or circumstances occurring after the date hereof.

    Condensed Consolidated Stat
'/>"/>
SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. OncoGenex Pharmaceuticals to Release First Quarter Financial Results
2. OncoGenex Receives Confirmation from FDA on the Design of a Second Phase 3 Trial Evaluating OGX-011 for the Treatment of Advanced Prostate Cancer
3. OncoGenex Pharmaceuticals Named Life Sciences Company of the Year by LifeSciences British Columbia
4. OncoGenex Reports Financial Results for Fourth Quarter and Fiscal Year 2008 and Provides Outlook for 2009
5. OncoGenex Pharmaceuticals to Webcast Financial Results for Fourth Quarter and Fiscal Year 2008 and Provide Outlook for 2009
6. OncoGenex Provides Update on Two-Year Survival Data from Ongoing Phase 1/2 Clinical Trial of OGX-011 in Non-Small Cell Lung Cancer
7. OncoGenex To Present At The RBC Capital Markets 2008 Healthcare Conference
8. OncoGenex Reports Third Quarter Financial Results
9. OncoGenex Pharmaceuticals to Release Third Quarter Financial Results
10. OncoGenex Achieves Key Regulatory Milestone for Lead Product Candidate, OGX-011
11. OncoGenex To Present At The BioContact Quebec 2008 Annual Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... VA (PRWEB) January 15, 2014 Two ... have continued their sponsorship of an annual competition for ... in, and access to, innovative STEM study. The competition ... TEAMS: Tests of Engineering Aptitude, Mathematics, and Sciences ...
(Date:1/15/2014)... 15, 2014 2013 was a banner ... State Technologies®. They saw continued independent research led by ... were awarded a $1 million grant from the Susanne ... and Behavior” a peer reviewed journal, Amy Grant highlighted ...
(Date:1/15/2014)... Biotechnology Company, Limited ("TaiGen") today announced that they have ... pharmaceutical company, to develop and commercialize nemonoxacin (Taigexyn ® ... Turkey and other members of ... for the treatment of bacterial infections including those caused ...
(Date:1/14/2014)... Histogen, Inc., a regenerative medicine company ... under simulated embryonic conditions, today announced that they have ... Inc. for physician-dispensed aesthetic products containing Histogen’s proprietary multipotent ... is an amendment to the existing license between Histogen ...
Breaking Biology Technology:Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 2Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 3Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 4Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 5Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 2Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3
... Alliance, an,organization comprised of 12 of the nation,s best ... million Americans to exercise,their power over cancer by stepping ... Day through Father,s Day., The campaign, dubbed the ... activate Americans everywhere to take matters into their own,hands, ...
... Genaera,Corporation (Nasdaq: GENR ) today announced its financial ... for the quarter ended March 31,2008 was $4.3 million, or ... loss of $4.2 million, or $(0.24) per basic and diluted ... and development expenses for the quarter ended March,31, 2008 were ...
... ,Shire plc (LSE: SHP, NASDAQ: SHPGY), the global ... scheme of,arrangement proposed in a circular to shareholders ... a meeting convened by the Court and,held today., ... 2008, the High Court is expected to,approve the ...
Cached Biology Technology:Moffitt Cancer Center Joins National Campaign To Implore Americans To Donate $1 To Accelerate Cancer Research 2Genaera Corporation Announces First Quarter Financial Results 2Genaera Corporation Announces First Quarter Financial Results 3Genaera Corporation Announces First Quarter Financial Results 4Results of Court Meeting and Extraordinary General Meeting - Shareholders Approve Scheme of Arrangement and New Share Plans 2Results of Court Meeting and Extraordinary General Meeting - Shareholders Approve Scheme of Arrangement and New Share Plans 3Results of Court Meeting and Extraordinary General Meeting - Shareholders Approve Scheme of Arrangement and New Share Plans 4Results of Court Meeting and Extraordinary General Meeting - Shareholders Approve Scheme of Arrangement and New Share Plans 5
(Date:4/17/2014)... honeybees in Europe, Asia and the United States are ... be impacting native honeybee populations at this time, according ... include including Nosema microsporidia and Varroa ... resilient to these invasive pests, which suggests to us ... Asia and the United States currently are not necessary ...
(Date:4/17/2014)... stark warning on the possible effects of gases such ... times that of carbon dioxide. Now a team of ... fully regenerable electron acceptors which helps explain why large ... being released to the atmosphere. However, there are worries ... into a vicious cycle to release large amounts of ...
(Date:4/17/2014)... Medical Branch at Galveston are the first to ... cervical cancer should begin colorectal cancer screening earlier ... finding a high incidence of secondary colorectal cancers ... new recommendations that the younger women in this ... after their initial cervical cancer diagnosis instead of ...
Breaking Biology News(10 mins):East African honeybees are safe from invasive pests… for now 2East African honeybees are safe from invasive pests… for now 3Methane climate change risk suggested by proof of redox cycling of humic substances 2Radiation therapy for cervical cancer increases risk for colorectal cancer 2
... The National Science Foundation has awarded Iowa State ... million grant to establish the NSF Engineering Research ... The award is part of the National ... Program. The third-generation Engineering Research Centers are designed ...
... utilize small, short-lived animals (insects, worms, mice) under ... parasites, superabundant food in the laboratory. Oddly ... such animals in their harsh, stressful natural environments. ... actually age much more slowly in captive luxury ...
... Bats, ability to echolocate may have evolved more than once, ... of London scientists. Species of bat with the ability ... tree of life - some are more related to their ... of whether echolocation in bats has evolved more than once, ...
Cached Biology News:Iowa State wins $18.5M grant to create NSF Center for Biorenewable Chemicals 2Iowa State wins $18.5M grant to create NSF Center for Biorenewable Chemicals 3Iowa State wins $18.5M grant to create NSF Center for Biorenewable Chemicals 4Old before their time? Aging in flies under natural vs. laboratory conditions 2Molecular evolution is echoed in bat ears 2
... 200 IS System is ideal for developing ... reagents. This system contains the new, improved, ... Luminex. The user can design specific templates ... system has fully integrated graphing and data ...
... The GeneSwitch Cell Lines stably express ... Each cell line is functionally tested ... with the expression control vector pGene/V5-His/lacZ ... after treatment with mifepristone (Figure 1). ...
... 15-20 enhancements when used as directed, ... is designed to amplify the desired signal detected by ... proteins with low expression., Membrane Enhancement ... the membrane; 1x solution; 250 ml, ...
... library screening, optimal siRNA transfection ... verified for each cell type ... Transfection Optimization Kit, which was ... conditions in 96 well plates, ...
Biology Products: